Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells - Wikidata - awgldk - TriplyDB

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells

http://www.wikidata.org/entity/Q36868759

about

S-sulfhydration of MEK1 leads to PARP-1 activation and DNA damage repair Collaborator of ARF (CARF) regulates proliferative fate of human cells by dose-dependent regulation of DNA damage signaling CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle Raf kinases in cancer-roles and therapeutic opportunities Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas.Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma.The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126 New insights into checkpoint kinase 1 in the DNA damage response signaling network.Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation.Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.Unveiling the principle of microRNA-mediated redundancy in cellular pathway regulation Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells MyD88 in DNA repair and cancer cell resistance to genotoxic drugs.Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression.Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.CIB1 prevents nuclear GAPDH accumulation and non-apoptotic tumor cell death via AKT and ERK signaling.Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor.Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

P2860

Q24296356-C66A0E65-57E6-427C-96BA-14B37DCCA819 Q24297805-25B0B8D3-D94B-41D1-9849-10D015405DE9 Q24622357-B8B396F3-A2C9-40AD-A35A-6BF8540E938C Q28237793-08306B27-DDA3-4166-B291-BA93359C7B29 Q28540339-D2CC30FA-6C25-413C-845D-3133934B588B Q30498959-DB1AA9E0-B232-47B8-A3A0-FFDBD6A776F6 Q33394689-C636A192-06A2-4137-87B3-9890244B451A Q33426534-BF843C45-C21F-45C5-9F0C-42E4775088F8 Q33730792-34AD54A7-BAA6-48A8-A75C-1DF7C2E7C989 Q33731418-8A604339-0317-4B08-AF2D-827BC391C609 Q33896749-E6BFBA62-7C48-46EA-8907-485B1BD5EFF6 Q33944281-4B2E6FE8-34A7-47AB-BCC4-87FCDE153DBA Q34017354-045C3EE4-8FE7-42D0-B377-4C09916851BA Q34057987-D57AFFBC-26CE-438F-9CB0-55AF80A7DFA1 Q34129155-A97EA612-4A7E-41A0-9781-AF19F43975DF Q34309934-695AF8FC-1CD0-45FC-B6E0-D44F2F5AF389 Q34667764-DC8A1144-B6C3-4D6F-9DF1-7211C8DF033C Q35130674-D77FE50C-BAFF-4EB7-96D7-7B46BE1CEED3 Q35525553-ABDE2734-EA82-4D9F-9059-8454106333E8 Q35592015-732CFF60-05E2-418A-9425-9F96D9566A2D Q35782878-320D254B-FE36-43A2-8E42-0B85CC8759C4 Q35809470-E5C97198-6A61-47A7-92D4-D3A4DE94937A Q35835097-D5535054-6B9C-446A-948B-0627485C7FCD Q35900578-2C1AB8BC-4FDA-45A5-9931-39088CF388B0 Q36105500-0F0B4E97-5577-448A-8F64-48A45CC8CC43 Q36191693-270FF1D0-8FB0-473E-90E6-099537A8E644 Q36412841-B907217D-6D6C-4DDC-AC54-7E77B5D76BD6 Q36651351-91AC0242-D920-4816-A5DA-088C57B3301F Q36901517-2DA8EFED-22CF-4518-8FC5-D3EA3D038C1C Q36976203-406679D0-F62C-40F5-A427-898D827C3EAB Q37227994-F75B4EEB-5402-49B5-B10C-4C4DC912276D Q37379984-F42670CC-B1F7-4671-9E10-40A9B626C78E Q37613538-ABB374C0-FD91-4AD1-9289-CAB3D16F5AF4 Q37970379-930B19D1-DB32-4696-B7C2-39E5BB4C4E1F Q39150740-FF062D95-9FC0-4CDC-B114-CDEFF82EF32C Q39277209-DA184CF4-9F67-4119-A40D-D2B36B675531 Q39281845-DF1175F8-858E-41A6-AD37-71E9655DAF0E Q39598910-616F6A43-F167-4677-BE7C-577196FB922B Q39621410-E03A9F2E-041E-44FE-988A-3B22F30DD183 Q40063670-D730F4FF-1CFC-4384-9AE1-B56E9E035F0D

P2860

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells

http://www.wikidata.org/entity/Q36868759

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Interruption of the Ras/MEK/ER ...... n human multiple myeloma cells

@en

type

label

Interruption of the Ras/MEK/ER ...... n human multiple myeloma cells

@en

prefLabel

Interruption of the Ras/MEK/ER ...... n human multiple myeloma cells

@en

P1433

Q36868759-DF8414B4-A592-47BF-B0A8-806ED2C6DA50

P1476

Q36868759-7C1FA15E-E448-4839-9838-C637FC4B2747

P2093

Q36868759-147FAE3D-F6E3-418B-B70B-6423B3CE3A1D

Q36868759-3D01D362-7E79-4BCD-8017-7513F5188B7E

Q36868759-52362805-3CC8-4436-9430-25D379702E71

Q36868759-74CB7D96-3F41-4F81-BE4E-18B4BCA51875

Q36868759-7A7061CB-6EB2-4790-B0BE-8E68BD9E49D7

Q36868759-AE767A54-648D-417F-BC3B-E251A11E24E0

Q36868759-EFC940E5-2BBA-4B55-824C-885B562E51AA

P2860

Q36868759-0A1DA24B-7F70-4C01-B8E1-C83571765F09

Q36868759-0B1F123A-D6E3-49BC-A7D2-8ABBC4FD236E

Q36868759-0BAD50A7-96E4-4647-AF8B-A0B488AECBA4

Q36868759-0D48F3A9-F434-48C1-B87B-9B9460C4A38F

Q36868759-0FEA088F-4EB9-494D-944B-E32C51D9615E

Q36868759-160876A6-7C3E-4DF9-A9E1-FBC22A41F7C7

Q36868759-242BE434-E3C8-4CC6-B10C-87C6721236F3

Q36868759-2E30F5E7-2EE8-4D02-9E84-01B5C6CE35C4

Q36868759-2EB50206-DA7E-438A-9C98-C048A9FBFEF0

Q36868759-3146D39D-3FBD-4AD1-9EA2-64B7C0B6192F

P304

Q36868759-B4C0AB21-13AD-4CAA-86CE-CE4B1C41DFFE

P31

Q36868759-55133248-3EF7-46B5-9097-907CD45C7957

P356

Q36868759-59E4645E-64EE-4E71-9086-6C1CBAEF612D

P407

Q36868759-9A05EBB9-72F7-4B07-8929-E565447E4183

P433

Q36868759-BF501873-E7A0-4AE5-AB4F-9E1F6776F0B5

P478

Q36868759-D86D4E9B-B181-4470-9E01-B97D3C6004FB

P50

Q36868759-45D50D4C-2FEC-4C8C-859E-A5E0AAD5A4B7

P577

Q36868759-7E47518A-7DAF-4027-9CBF-240E49F6BBF1

P5875

Q36868759-47AD4A32-9092-4062-8E93-0B66261935E4

P698

Q36868759-5EEB1363-8E55-424A-81E1-EDFE5126E94E

P921

Q36868759-8C897BD4-227F-4929-92EE-237CB1AFD041

P932

Q36868759-4BED5F02-37C5-4DE0-86F6-FB92D91F988C

P356

BLOOD-2008-05-159392

P1433

P1476

Interruption of the Ras/MEK/ER ...... n human multiple myeloma cells

@en

P2093

Charis A Venditti

http://www.w3.org/2001/XMLSchema#string

Jorge A Almenara

http://www.w3.org/2001/XMLSchema#string

Lora B Kramer

http://www.w3.org/2001/XMLSchema#string

Shuang Chen

http://www.w3.org/2001/XMLSchema#string

Steven Grant

http://www.w3.org/2001/XMLSchema#string

Xin-Yan Pei

http://www.w3.org/2001/XMLSchema#string

Yun Dai

http://www.w3.org/2001/XMLSchema#string

P2860

RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly

The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair

RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors

Megabase chromatin domains involved in DNA double-strand breaks in vivo

DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139

Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

Cell-cycle checkpoints and cancer

P304

2439-2449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-05-159392

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5237511

http://www.w3.org/2001/XMLSchema#string

P698

18614762

http://www.w3.org/2001/XMLSchema#string

P921

P932

2532812

http://www.w3.org/2001/XMLSchema#string